HIV / AIDS

ViiV Healthcare’s investigational therapy, GSK’254, demonstrated antiviral activity, safety, and tolerability in its phase 2a proof-of-concept findings.

With the highest HIV incidence rate in this part of the country, the need to get people from diagnosis to timely antiretroviral therapy (ART) remains an urgent need.

New research from the Emerman Lab at Fred Hutchinson shows potential for advancing HIV-1 life cycle understanding.

Presented at CROI, investigators have identified sex-modified inflammatory predictors of cardiovascular and VTE risks among patients with HIV.

Merck has developed its investigational islatravir subdermal implant for prevention of HIV infection, and it is going to be studied for a long-term delivery of up to 1 year.

14 weeks of oral alendronate taken prior to ART had a sustained impact on prevention of bone loss at the hip.

Increased hospitalization risk was driven mainly by the high burden of comorbidities in both groups.

Change was associated with risk factors that have not been reported like chronic lung disease.

Merck’s islatravir subdermal implant demonstrated it achieved active drug concentrations above the pre-specified pharmacokinetics (pk) threshold at 12 weeks across three doses.

People with HIV had similar control of most conditions except for triglycerides.

One month after the Food and Drug Administration (FDA) approval of monthly rilpivirine/cabotegravir (Cabenuva) for HIV, Janssen has submitted evidence of efficacy with dosing every 2 months.

A talk on optimistic, but pragmatic hopes for HIV cure and vaccine research, led by federal-level experts.

Attention to the endemic virus has lessened over years, and screening and prevention access remains limited among the most at-risk groups.

A John Hopkins expert and major study leader details the evolving epidemiology of the virus.

HIV-associated wasting remains common complication despite treatment with antiretroviral therapy.

Ruth Coker Burks’ new book, All the Young Men, chronicles her years at the bedside of victims.

HIV testing and initiation of antiretroviral therapy (ART) fell in South Africa during the national lockdown in response to the coronavirus disease 2019 (COVID-19) pandemic, a new study shows.

Derek Blechinger, MD, MPH, and a team at the Kaiser Permanente San Francisco Medical Center have developed an HIV prediction model to find patients earlier in the care cycle who could benefit from pre-exposure prophylaxis (PrEP) therapy.

Educating young people is especially critical and many countries have seen great success in youth education as a prevention strategy.

A syndemic association between the two infections may have an increasing impact on affected people and communities.

Among people living with HIV, lower white blood cell counts were associated with smaller brain volume in the hippocampus and thalamus, a new study found, suggesting the possibility of generalizable neurologic signatures of HIV infections.

The cabotegravir and rilpivirine formulation was approved on the basis of 2 trials assessing its viral suppression capability in 1100-plus adults with HIV.

A study found patients with acute infection and those with viral rebound after antiretroviral therapy interruption had the highest viral resistance to type 1 interferons.

Anal squamous cell carcinoma mortality rate is rising faster than other types of cancer in the United States.